Suchergebnisse - "Eskelund, Christian Winther"

PubPharm (13)

1

Clonal hematopoiesis of indeterminate potential in persons with HIV

enthalten in: AIDS (London, England) | 2024

von Knudsen, A. | Eskelund, C. | Benfield, T. | +10

2

Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors

enthalten in: Haematologica | 2023

von Gerdtsson, A. | Matos Rodrigues, J. | Eskelund, C. | +8

3

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma

enthalten in: Cancer reports (Hoboken, N.J.) | 2022

von Lokhande, L. | Kuci Emruli, V. | Eskelund, C. | +7

4

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma

enthalten in: Cancer Reports | 2022

von Lokhande, L. | Kuci Emruli, V. | Eskelund, C. | +7

5

Pre‐treatment health‐related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma : The Nordic Lymphoma Group MCL4 (LENA‐BERIT) experience

enthalten in: Hematological Oncology | 2022

von Lindberg, �. | Eskelund, C. | Albertsson‐Lindblad, A. | +6

6

Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma : The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

enthalten in: Hematological oncology | 2022

von Lindberg, �. | Eskelund, C. | Albertsson-Lindblad, A. | +6

7

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials : MCL2 and MCL3

enthalten in: HemaSphere | 2021

von Eskelund, C. | Dimopoulos, K. | Kolstad, A. | +17

8

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

enthalten in: Blood | 2020

von Eskelund, C. | Husby, S. | Favero, F. | +9

CommentIn: Blood. 2020 May 28;135(22):1927-1928. - PMID 32463886

9

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

enthalten in: Haematologica | 2018

von Eskelund, C. | Albertsson-Lindblad, A. | Kolstad, A. | +6

10

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

enthalten in: BMC cancer | 2018

von Freiburghaus, C. | Emruli, V. | Johansson, A. | +6